CHMA Chiasma, Inc. gains 26% Oct 2, 2018

Posted By: Rajesh Srivastava - Tuesday, October 02, 2018

Share

& Comment

Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.http://www.priceseries.com/trade/CHMA-Chiasma-Inc-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2018091320181002.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.